The introduction of systematic genomic testing for patients with non-small cell lung cancer (NSCLC) at Dana-Farber Cancer Institute (DFCI).

7517 Background: Systematic genomic testing to identify potential predictive biomarkers to select targeted therapy is emerging for NSCLC. DFCI introduced systematic testing for mutations in BRAF, HER2, PIK3CA and EML4-ALK translocations in addition to routine characterization of EGFR and KRAS in July 2009 as part of a prospective study. One and a half years have passed, thus we report our initial experience. Methods: Providers consented patients with advanced non-squamous NSCLC. Pathology specimens were dissected and analyzed by PCR-Sanger sequencing for mutations in selected exons of EGFR, KRAS, BRAF, PIK3CA and HER2. ALK rearrangements were detected with fluorescence in-situ hybridization. Results: Between 7/1/2009 and 4/12/2010, 226 consecutive patients were tested. The median age was 62 years. 134 (59%) were female, 195 (86%) had adenocarcinoma, 174 (77%) were former/current smokers and 182 (81%) had stage IIIB/IV disease. Five patients had two different specimens tested; three of these had repeat ana...